Stock Events

Stock Events

Tectonic Therapeutic 

$30.74
0
+$0+0% Thursday 05:46

Statistics

Day High
30.74
Day Low
30.74
52W High
-
52W Low
-
Volume
20
Avg. Volume
-
Mkt Cap
577.2M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-1.16
-1.11
-1.07
-1.02
Expected EPS
-1.157037
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-148.3MNet Income

Analyst Ratings

$60.00Average Price Target
The highest estimate is 60.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TECX.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing, a technology that competes with AvroBio's gene therapy techniques for treating genetic disorders.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, competing in the same space as AvroBio for genetic disease treatments.
Regenxbio
RGNX
Mkt Cap440.26M
REGENXBIO is a biotech company focusing on adeno-associated virus (AAV) based gene therapy, which competes with AvroBio's lentiviral-based gene therapy approaches.
Pfizer
PFE
Mkt Cap161.09B
Pfizer has a growing interest in gene therapy for rare diseases, positioning it as a competitor to AvroBio through its large-scale resources and investments in similar therapeutic areas.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical develops and commercializes innovative therapies for rare genetic diseases, competing with AvroBio in targeting similar patient populations.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals engages in developing treatments for genetic diseases, including CRISPR-based therapies, making it a competitor in the gene therapy market.
Novartis
NVS
Mkt Cap297.32B
Novartis has a strong presence in gene therapy, particularly with its acquisition of AveXis, making it a direct competitor in the gene therapy space for rare diseases.

About

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
Show more...
CEO
ISIN
US8789721086

Listings

XNAS
US
TECX
BOATS
BOATS
TECX.BOATS

0 Comments

Share your thoughts

FAQ

What is Tectonic Therapeutic stock price today?▼
The current price of TECX.BOATS is $30.74 USD — it has increased by +0% in the past 24 hours. Watch Tectonic Therapeutic stock price performance more closely on the chart.
What is Tectonic Therapeutic stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Tectonic Therapeutic stocks are traded under the ticker TECX.BOATS.
What is Tectonic Therapeutic market cap?▼
Today Tectonic Therapeutic has the market capitalization of 577.2M
When is the next Tectonic Therapeutic earnings date?▼
Tectonic Therapeutic is going to release the next earnings report on May 07, 2026.
What were Tectonic Therapeutic earnings last quarter?▼
TECX.BOATS earnings for the last quarter are -1.03 USD per share, whereas the estimation was -1.09 USD resulting in a +5.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Tectonic Therapeutic revenue for the last year?▼
Tectonic Therapeutic revenue for the last year amounts to 0 USD.
What is Tectonic Therapeutic net income for the last year?▼
TECX.BOATS net income for the last year is -148.3M USD.
When did Tectonic Therapeutic complete a stock split?▼
Tectonic Therapeutic has not had any recent stock splits.